Christopher Corsico, M.D., has left GSK to become Sanofi’s global head of development, effective immediately.
The announcement was shared with Sanofi team members March 31, according to an internal company communication obtained by Fierce Biotech.
In his new role, Corsico will report to Sanofi’s executive vice president of R&D Houman Ashrafian, Ph.D., according to the internal memo.
Corsico fills a role that has sat vacant since Gilead Sciences plucked Dietmar Berger, M.D., Ph.D., to replace Chief Medical Officer Merdad Parsey, M.D., Ph.D. Berger left his role as Sanofi’s CMO and global head of development at the start of 2025. It is not immediately clear what Sanofi's plans are for the CMO role.
Corsico joins Sanofi from British pharma GSK, where he served as senior vice president and global head of development for more than six years.
Before that, the leader spent over 20 years at Boehringer Ingelheim across various roles, including chief medical officer.
Corsico received his medical degree from Cornell University in New York and a master’s degree in public health for chronic disease epidemiology from Yale University in Connecticut.
GSK confirmed Corsico's departure and told Fierce Biotech that Harmony Garges, M.D., has been appointed to lead the pharma's development unit. Garges has more than 20 combined years of service across GSK ViiV Healthcare, an independent company owned by GSK, Pfizer and Shionogi.